Sildenafil (Viagra(TM)), a potent and selective inhibitor of type 5 CGMP phosphodiesterase with utility for the treatment of male erectile dysfunction

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 15, 1996, Pages 1819-1824

  Terrett, Nicholas K ^a   Bell, Andrew S ^a   Brown, David ^b   Ellis, Peter ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; ZAPRINAST;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG DESIGN; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; NONHUMAN; PENIS ERECTION; RABBIT; SEXUAL DYSFUNCTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0030572496     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00323-X     Document Type: Article

References (20)

1. 2. Goy, M.F. cGMP: the Wayward Child of the Cyclic Nucleotide Family. Trends Neurosci. 1991, 14, 293-299
2. 3. Beavo, J.A.; Conti, M.; Heaslip, R.J. Multiple Cyclic Nucleotide Phosphodiesterases. Mol. Pharmacol. 1994, 46, 399-400
3. 4. Murray, K.J.; England, P.J. Inhibitors of Cyclic Nucleotide Phosphodiesterases as Therapeutic Agents. Biochem. Soc. Trans. 1992, 20, 460-464.
4. 5. Beavo, J.A.; Reifsnyder, D.H. Primary Sequences of Cyclic Nucleotide Phosphodiesterase Isozymes and the Design of Selective Inhibitors. Trends Pharmacol. Sci. 1990, 11, 150-155.
5. A Inhibitors. Drug News Perspectives, 1993, 6, 150-156.
6. 7. Danilewicz, J.C.; Barclay, P.L.; Brown, D.; Campbell, S.F.; James, K.; Samuels, G.M.R.; Terrett, N.K.; Wythes, M.J. UK-69,578, a Novel Inhibitor of EC 3.4.24.11 which Increases Endogenous ANF Levels and is Natriuretic and Diuretic. Biochem. Biophys. Res. Commun. 1989, 164, 58-65.
7. 8. Ballard, S.A.; Burslem, M.F.; Gingell, J.C.; Price, M.E.; Tang, K.; Turner, L.A.; Naylor, A.M. In Vitro Cyclic GMP Hydrolysing Activity in the Cytosolic Fraction from Corpus Cavernosum. J. Urology, In press.
8. 9. Kim, N.; Azadzoi, K.M.; Goldstein, I.; De Tejeda, I.S. A Nitric Oxide-like Factor Mediates Non-adrenergic Noncholinergic Neurogenic Relaxation of Penile Corpus Cavernosum Smooth Muscle. J. Clin. Invest. 1991, 88, 112-118. Raifer, J.; Aronson, W.J.; Bush, P.A.; Dorey, F.J.; Ignarro, L.J. Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic Noncholinergic Neurotransmission. N. Engl. J. Med. 1992, 326, 90-94. Burnett, A.L.; Lowenstein, C.J.; Bredt, D.S.; Chang, T.C.K.; Snyder, S.H. Nitric Oxide: a Physiologic Mediator of Penile Erection. Science 1992, 257, 401-403.
9. 9. Kim, N.; Azadzoi, K.M.; Goldstein, I.; De Tejeda, I.S. A Nitric Oxide-like Factor Mediates Non-adrenergic Noncholinergic Neurogenic Relaxation of Penile Corpus Cavernosum Smooth Muscle. J. Clin. Invest. 1991, 88, 112-118. Raifer, J.; Aronson, W.J.; Bush, P.A.; Dorey, F.J.; Ignarro, L.J. Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic Noncholinergic Neurotransmission. N. Engl. J. Med. 1992, 326, 90-94. Burnett, A.L.; Lowenstein, C.J.; Bredt, D.S.; Chang, T.C.K.; Snyder, S.H. Nitric Oxide: a Physiologic Mediator of Penile Erection. Science 1992, 257, 401-403.
10. 9. Kim, N.; Azadzoi, K.M.; Goldstein, I.; De Tejeda, I.S. A Nitric Oxide-like Factor Mediates Non-adrenergic Noncholinergic Neurogenic Relaxation of Penile Corpus Cavernosum Smooth Muscle. J. Clin. Invest. 1991, 88, 112-118. Raifer, J.; Aronson, W.J.; Bush, P.A.; Dorey, F.J.; Ignarro, L.J. Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic Noncholinergic Neurotransmission. N. Engl. J. Med. 1992, 326, 90-94. Burnett, A.L.; Lowenstein, C.J.; Bredt, D.S.; Chang, T.C.K.; Snyder, S.H. Nitric Oxide: a Physiologic Mediator of Penile Erection. Science 1992, 257, 401-403.
11. 10. Mirone, V.; Palmieri, A.; Nistico, G. Valida Risposta Erettile Indotta dal Ciclico GMP in un Gruppo di Pazienti Affetti da Impotenza e suoi Effetti sul Sistema Ossido Nitrico-guanilato Ciclasi. Acta. Urol. Ital. 1992, Suppl. 4, 11-12.
12. 11. Holland, A.; Jackson, D.; Chaplen, P.; Lunt, E.; Marshall, S.; Pain, D.; Wooldridge, K.; Antiallergic Activity of 8-Azapurin-6-ones with Heterocyclic 2-Substituents. Eur. J. Med. Chem. 1975, 10, 447-449.
13. 12. Komas, N.; Lugnier, C.; Stoclet, J.C. Endothelium-dependent and Independent Relaxation of the Rat Aorta by Cyclic Nucleotide Phosphodiesterase Inhibitors. Brit. J. Pharmacol. 1991, 104, 495-503.
14. 13. Lee, K.C.; Canniff, P.C.; Hamel, D.W.; Pagani, E.D.; Gorcyzca, W.P.; Ezrin, A.M.; Silver, P.J. Comparative Hemodynamic and Renal Effects of the Low Km cGMP Phosphodiesterase Inhibitors Cicletanine and Zaprinast in Anesthetized Dogs. Drug Develop. Res. 1991, 23, 127-144.
15. 14. Meanwell, N.A.; Drug News Perspectives 1991, 4, 400-413.
16. 50 values were calculated using a sigmoidal curve fitting algorithm.
17. 50 values were calculated using a sigmoidal curve fitting algorithm.
18. 16. Dipole moments were calculated using SPARTAN, Wavefunction, Inc., Irvine, CA, USA.
19. 17. X-ray crystallographic studies of sildenafil (see below) and related compounds demonstrated that in the solid state at least, this hydrogen bond was important. (equation presented)
20. 18. Wilson, S.R.; Wilson, R.B.; Shoemaker, A.L.; Wooldridge, K.R.H.; Hodgson, D.J. Antiallergic 8-Aza-purines 3. Structural Characterization of 2-(2-Propoxyphenyl)-8-azahypoxanthine, 2-(2-Propoxy-5-(propylsulfonyl)phenyl)-8-azahypoxanthine, and 2-(2-Propoxy-5-(N-methyl-N-isopropylsulfamoyl)phenyl-8-azahypoxanthine. J. Am. Chem. Soc. 1982, 104, 259-264.